MedTrace Logo

Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

NCT00965887 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-07-07

No results posted yet for this study

Summary

This study will evaluate the bioequivalence of two solid dose formulations of MK0974.

Conditions

Interventions

DRUG

MK0974 Ethanolate formulation

Single dose MK0974 280 mg tablet in one of two treatment periods

DRUG

Comparator: MK0974 Hydrate formulation

Single dose MK0974 280 mg tablet in one of two treatment periods

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00965887 on ClinicalTrials.gov